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Abstract
Motility of the protozoan parasite Toxoplasma gondii plays an important role in the parasite’s life cycle and virulence within
animal and human hosts. Motility is driven by a myosin motor complex that is highly conserved across the Phylum
Apicomplexa. Two key components of this complex are the class XIV unconventional myosin, TgMyoA, and its associated
light chain, TgMLC1. We previously showed that treatment of parasites with a small-molecule inhibitor of T. gondii invasion
and motility, tachypleginA, induces an electrophoretic mobility shift of TgMLC1 that is associated with decreased myosin
motor activity. However, the direct target(s) of tachypleginA and the molecular basis of the compound-induced TgMLC1
modification were unknown. We show here by ‘‘click’’ chemistry labelling that TgMLC1 is a direct and covalent target of an
alkyne-derivatized analogue of tachypleginA. We also show that this analogue can covalently bind to model thiol substrates.
The electrophoretic mobility shift induced by another structural analogue, tachypleginA-2, was associated with the
formation of a 225.118 Da adduct on S57 and/or C58, and treatment with deuterated tachypleginA-2 confirmed that the
adduct was derived from the compound itself. Recombinant TgMLC1 containing a C58S mutation (but not S57A) was
refractory to click labelling and no longer exhibited a mobility shift in response to compound treatment, identifying C58 as
the site of compound binding on TgMLC1. Finally, a knock-in parasite line expressing the C58S mutation showed decreased
sensitivity to compound treatment in a quantitative 3D motility assay. These data strongly support a model in which
tachypleginA and its analogues inhibit the motility of T. gondii by binding directly and covalently to C58 of TgMLC1, thereby
causing a decrease in the activity of the parasite’s myosin motor.
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Introduction
Parasites of the phylum Apicomplexa are responsible for an
enormous amount of morbidity and mortality worldwide; mem-
bers include Plasmodium spp., which cause malaria, and Toxoplasma
gondii, which infects approximately one-third of the world’s
population and can cause life-threatening disease in the developing
fetus and immunocompromised individuals. Most apicomplexan
parasites need to invade and replicate within cells of their hosts in
order to survive. This need can be exploited for drug development,
and simultaneously provides an opportunity to investigate the
unique biology underlying the apicomplexan life cycle.
A functional myosin motor complex is important for efficient
invasion and egress from infected host cells, as well as for parasite-
driven dissemination throughout the body [1]. Components of this
motor complex include the unconventional class XIV myosin
TgMyoA, its associated regulatory light chain, TgMLC1 [2], an
essential light chain (TgELC1) [3], and gliding-associated proteins
TgGAP40, TgGAP45, TgGAP50 and TgGAP70 [4,5]. These
proteins are localized to the space between the parasite plasma
membrane and the flattened vesicles of the inner membrane
complex (IMC) [6–8]. The motor complex is anchored to the
plasma membrane via acylation of TgGAP45 and TgGAP70, and
to the IMC through the integral membrane proteins TgGAP40
and TgGAP50 [4,5]. While many proteins that interact directly
and indirectly with TgMyoA have been identified and their
physical interactions characterized, how the motor complexes are
spatially organized within the parasite and how the components
coordinate to produce translational motion are not well under-
stood.
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Recent studies have focused on the function of TgMyoA, the
protein at the heart of the motor complex. A conditional
knockdown approach revealed that myoA-depleted parasites were
unable to undergo gliding motility, showed severely reduced host
cell invasion and egress, and were less virulent in mice [9]. More
recently, a system using Cre recombinase-mediated excision
generated myoA knockout parasites. These parasites were viable
but again showed significantly decreased levels of motility,
invasion, egress and growth. These findings indicate that while
TgMyoA is not strictly essential, it is important for several critical
processes in the parasite life cycle [10]. Myosin light chains are
typically involved in maintaining the rigidity of myosin motors and
regulating actin-activated myosin ATPase activity [11–13]. A
spectrum of essential and regulatory light chains has been recently
discovered in T. gondii, with detailed phylogenetic analysis
identifying six putative myosin regulatory light chains in addition
to TgMLC1 and TgELC1 [14]. Since myosin light chains can
modulate the activity of the myosin motor proteins with which
they associate, the interfaces between these different light chains
and their myosin motors represent promising targets for the design
and development of anti-parasitic drugs [15].
We previously performed a high-throughput screen and
identified 24 small-molecule inhibitors of host cell invasion by T.
gondii; 21 of these compounds also inhibited parasite motility [16].
One of the motility inhibitors, tachypleginA, induced a modifica-
tion on TgMLC1 that increased its electrophoretic mobility [17].
While the modification was mapped to the V46-R59 tryptic
peptide of TgMLC1 and found to be associated with a decrease in
TgMyoA motor function, the nature of the modification and the
direct target(s) of the compound in the parasite were unknown. In
this study, we reproduce the compound-induced mobility shift in a
heterologous system, and show that the compound binds directly
and covalently to C58 of TgMLC1. Knock-in parasites expressing
TgMLC1 with a C58S mutation showed significantly reduced
sensitivity to compound treatment in a quantitative, Matrigel-
based motility assay. These data provide insight into the
mechanism by which chemical modification of a regulatory light
chain within the class XIV myosin motor complex affects the
motility of this important apicomplexan parasite.
Materials and Methods
Parasite culture
Parental (RHDku80Dhxgprt) [18,19], and FLAG-TgMLC1-WT
(WT) and FLAG-TgMLC1-C58S (C58S) knock-in T. gondii
parasites were maintained by serial passage in confluent primary
human foreskin fibroblast (HFF) (ATCC CRL-1634) monolayers
grown in Dulbecco’s Modified Eagle’s Medium (DMEM),
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS) and 10 mM HEPES, pH 7.0, as previously described [20].
The medium was changed to DMEM supplemented with 1% (v/v)
heat-inactivated FBS and 10 mM HEPES pH 7.0 just prior to
infecting the confluent monolayers with parasites.
Compound storage and use
All small-molecule inhibitors were synthesized by reacting
N-npropyl-4-piperidone with the required aldehyde for 24 h in a
solution of acetic acid saturated with dry HCl gas according to
previously reported literature protocols [21–23] (see Figure S1 and
Supporting Information S1 for analytical characterization of novel
compounds). Inhibitors were stored at -20uC. Compound stock
solutions were prepared by dissolving the solid compound to a
concentration of 40 mM in high quality dimethylsulfoxide
(DMSO). Immediately before use, compounds were diluted in
the appropriate buffer to a final concentration of 100 mM (unless
otherwise noted) and incubated in the dark at 25uC for 20 min. A
previous report by us showed that double bond isomerisation
occurred in a related system in the presence of light [24]. Parasites
or baculovirus-infected Sf 9 cells were then incubated in the
diluted compound for 20 min at 25uC. Invasion and gliding
motility (trail deposition) assays were performed as previously
described [16]; 3D motility assays are described further below.
Sf 9/baculovirus culture and recombinant TgMLC1
expression and purification
To generate the FLAG-tagged wild-type TgMLC1 baculovirus
expression vector (pAcSG2(FLAG-TgMLC1-WT)), the coding
sequence for TgMLC1 was amplified by PCR from the T. gondii
expression vector pTUB-FLAGTgMLC1WT [17] using primers
EcoRI-FLAG-TgMLC1-Fwd and TgMLC1-BglII-Rev (see Table
S1 for complete list of primers used in this study). The PCR product
was cloned in the pGEM T-Easy vector (Promega, Madison, WI),
and then subcloned into the pAcSG2 baculovirus expression vector
(BD Biosciences, San Jose, CA) using the restriction sites EcoRI and
BglII. The FLAG-tagged S57A and C58S TgMLC1 constructs were
generated with the QuikChange site-directed mutagenesis method
using the primer pairs TgMLC1S57AFwd and TgMLC1S57ARev,
and TgMLC1C58S2Fwd and TgMLC1C58S2Rev, respectively,
according to the manufacturer’s instructions (Agilent Technologies,
Santa Clara, CA). Constructs were verified by diagnostic restriction
digests and DNA sequencing.
Sf 9 cells were infected with recombinant wild-type or mutant
TgMLC1 virus and incubated, shaking, for ,72 h at 27uC. For
click chemistry labelling experiments, 16105 infected Sf 9 cells
were centrifuged for 4 min at 1,000 x g, resuspended in 500 mL
Hank’s Buffered Salt Solution containing 10 mM HEPES, pH 7.0
(HH), and 100 mM compound or an equivalent amount of
DMSO, and incubated at 25uC for 20 min. Cells were centrifuged
at 1,000 x g for 4 min, washed three times with phosphate-buffered
saline (PBS), and extracted in 30 mL lysis buffer (PBS, pH 7.4, 1%
(v/v) NP-40 and 1:100 protease inhibitor cocktail (Sigma-Aldrich,
St. Louis MO)) on ice for 2 h. Lysates were then clarified by
centrifugation at 21,000 x g for 10 min at 4uC prior to labelling
(see below).
For mass spectrometry experiments, 56107 infected Sf 9 cells
were centrifuged for 4 min at 1,000 x g and resuspended in 5 mL
of HH. The Sf 9 suspension was split into two equal aliquots, each
of which was added to 25 mL of HH containing either 100 mM
compound or an equivalent amount of DMSO, and incubated at
25uC for 20 min. Cells were centrifuged for 4 min at 1,000 x g,
resuspended in 550 mL of Sf 9 lysis buffer (10 mM imidazole,
pH 7.4, 300 mM NaCl, 2 mM EGTA, pH 8.15, 5 mM MgCl2,
7% (w/v) sucrose, 3 mM NaN3 and 1:100 protease inhibitor
cocktail), and lysed by sonication. The lysate was clarified by
centrifugation at 21,000 x g (30 min, 4uC). Before use, FLAG
affinity resin (Sigma-Aldrich) was equilibrated in FLAG affinity
purification buffer (10 mM imidazole, pH 7.4, 300 mM NaCl,
1 mM EGTA, pH 8.15, 5 mM MgCl2 and 1:100 protease
inhibitor cocktail). Protein lysates and 100 mL FLAG affinity resin
were gently agitated for 1 h at 4uC. Resins were extensively
washed with FLAG wash buffer (10 mM imidazole, pH 7.4,
300 mM NaCl, 1 mM EGTA, pH 8.15, 5 mM MgCl2 and 1:500
protease inhibitor cocktail) to remove any unbound proteins.
Recombinant FLAG-TgMLC1 was recovered from the resin using
two sequential elutions with 250 mL 0.1 mg/mL FLAG peptide
(Sigma-Aldrich) in FLAG wash buffer. Eluates were resolved by
SDS-PAGE and stained with Colloidal Coomassie Blue. Bands
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were excised and subjected to in-gel tryptic digestion as described
previously [17].
Click chemistry labelling with tachypleginA-4/biotin-
azide
Click chemistry was performed essentially as described [25,26].
Briefly, protein samples (30 mL aliquots, diluted 1 in 2 with PBS
for a starting volume of 60 mL) were treated with 50 mM biotin-
azide (50X stock in DMSO), 1 mM tris(2-carboxyethyl)phosphine
(TCEP) (fresh 50X stock in ddH2O), 100 mM tris-(benzyltriazo-
lylmethyl)amine (TBTA) ligand (17X stock in DMSO:t-butanol
1:4) and 1 mM CuSO4 (50X stock in ddH2O). Samples were
allowed to rock gently at 25uC for 1 h, and then centrifuged at
21,000 x g at 4uC to pellet the precipitated proteins. Protein pellets
were then mixed with 1X SDS-PAGE sample buffer containing
1.25% (v/v) b-mercaptoethanol and boiled for 10 min.
Western blotting
Protein samples were resolved by 12% SDS-PAGE and gels
were transferred to PVDF-FL membranes, which were blocked
with 5% (w/v) bovine serum albumin (BSA) in PBS for 1–12 h.
The monoclonal anti-FLAG antibody (Sigma-Aldrich) was used at
a 1:7,500 dilution and the affinity purified polyclonal rabbit anti-
TgACT1 antibody (a generous gift from Dr. David Sibley [27])
was used at a 1:10,000 dilution. Goat anti-mouse IRDye 680RD
and goat anti-rabbit IRDye 800 CW infrared dye-conjugated
secondary antibodies were used at a 1:20,000 dilution; the IRDye
800 CW streptavidin was used at a 1:10,000 dilution. Blots were
scanned using an Odyssey LI-COR CLx-0228 imaging system and
processed using Image Studio v.2.1.10 software (LI-COR Biosci-
ences, Lincoln, NE).
Analysis of recombinant TgMLC1 by mass spectrometry
All mass spectrometry preparations were performed in the VGN
Proteomics Facility at the University of Vermont. Dimethyl
labelling was adapted from protocols described previously [28,29].
Briefly, lyophilized tryptic peptides were dissolved in 50 mL of 1 M
HEPES-NaOH, pH 7.5, and incubated at 25uC for 10 min with
4 mL each of freshly made 4% (v/v) d0-formaldehyde in H2O and
600 mM sodium cyanoborohydride (NaCNBH3) in 1 M NaOH,
or 4% (v/v) d2-formaldehyde in H2O and 600 mM sodium
cyanoborodeuteride (NaCNBD3) in 1 M NaOH for ‘‘light’’ and
‘‘heavy’’ labelling, respectively. Samples were incubated for an
additional 10 min with a second round of labelling reagents,
followed by quenching of the reaction with 50 mL of 10% (v/v)
trifluoroacetic acid and incubation at 25uC for 1 h. The light and
heavy labelled samples were mixed and desalted using PepClean
C18 spin columns (Thermo Fisher Scientific, Rockford, IL). Spin
columns were prewashed twice with 200 mL Buffer B (99.9% (v/v)
acetonitrile, 0.1% (v/v) formic acid) and equilibrated with two
washes of 200 mL 0.1% (v/v) formic acid. The sample was passed
over the column twice to ensure maximal binding to resin, eluted
with two rounds of 30 mL Buffer B and dried in a SpeedVac
(Thermo Fisher Scientific, San Jose, CA) at 25uC for 2 h.
Mass measurements were made in an LTQ-Orbitrap hybrid
mass spectrometer (Thermo Fisher) with a liquid chromatography
interface set up as previously described [17]. Precursor scans (360–
1600 m/z) were conducted in the Orbitrap at 30,000 resolution
followed by ten data-dependent MS/MS scans in the LTQ linear
ion trap on the most abundant ions identified in the precursor
scan. Dynamic exclusion was enabled with a repeat count of three
for a duration of 30 s. The lock mass feature for internal calibration
was enabled and set to calibrate on the mass of a polydimethylcy-
closiloxane ion ([(Si(CH3)2O)5 + H+]+, m/z = 371.10120) [30,31].
MS/MS spectra were manually examined for the presence of
characteristic ‘‘marker’’ b- and y-ions (b5-ion m/z=564.2, b7-ion
m/z=692.3; y4-ion m/z=687.3, y6-ion m/z=903.4) calculated
using the MS-Product utility program of ProteinProspector v.
5.10.11 (http://prospector.ucsf.edu/prospector/mshome.htm; ac-
cessed 2013 Dec 10), for the initial identification of the
tachypleginA-2-induced, modified V46-R59 peptide. To collect
targeted, high mass accuracy MS/MS spectra, the fragmentation
method described above was revised to perform the MS/MS scans
in the Orbitrap instead of the LTQ linear ion trap, with a
normalized collision energy of 35, activation Q of 0.25, activation
time of 30 s and an isolation m/z width of 1.2. One MS/MS scan
targeted the m/z=849.35115 peak corresponding to that of the
modified peptide for fragmentation. MS3 analysis was performed
with the precursor scan in the Orbitrap followed by MS/MS and
MS3 scans in the LTQ linear ion trap, with the MS3 scan targeting
the m/z=1006.40950 peak corresponding to the y7-ion.
SEQUEST analysis of tandem mass spectra was conducted
using the TgMLC1 amino acid sequence, requiring no enzyme
specificity, allowing a 20 ppm window around the precursor mass
and allowing differential mass additions of 15.99491 on methio-
nines for oxidation, 79.96633 on serines, threonines and tyrosines
for phosphorylation, and the following on cysteines: 0 for a free
sulfhydryl, 57.02146 for carbamidomethylation, 71.03711 for
acrylamide adduction and 225.11859 for compound-induced
modification. For the dimethyl-labelled datasets, a static increase
of 28.0313 was set on N-termini and lysines, in addition to a
dynamic modification of 6.03766 on N-termini and lysines for
heavy labelled peptides.
Reaction of tachypleginA-4 with a model thiol
Model thiol substrate studies were performed as previously
described [32,33]. tachypleginA-4 (100 mg) was treated with the
cysteine model ethyl-2-mercaptoacetate (2.01 eq.) in dichloro-
methane (DCM, 5 mL) in the presence of triethylamine (2.01 eq.).
Upon completion, the reaction mixture was partitioned between
H2O (25 mL) and DCM (50 mL) and the two layers were
separated. The aqueous layer was further extracted with DCM
(2650 mL) and the combined organic extracts were dried
(MgSO4), filtered and concentrated in vacuo to give a bright yellow
oil. Purification by column chromatography (hexanes/ethyl
acetate: 9/1 to 1/1) afforded the thiol-adduct of tachypleginA-4
as an inseparable mixture of diastereomers (see Results and
Supporting Information S1 for more details).
Cloning and transfection of TgMLC1 knock-in mutants
To construct the FLAG-TgMLC1-WT knock-in plasmid
(pFLAGTgMLC1WTAR2tfwd), RHDku80Dhxgprt tachyzoite ge-
nomic DNA was extracted using DNAzol Reagent (Invitrogen,
Grand Island, NY) followed by ethanol precipitation, and used as
template for amplifying the 5’ flanking region for TgMLC1 (922
bp) with primers TgMLC15’flankKpnIFwd and KozakATG-
FLAGTgMLC1Rev. The coding sequence for FLAG-TgMLC1
was amplified by PCR from the T. gondii expression vector pTUB-
FLAGTgMLC1WT [17] using primers KozakATG-
FLAGTgMLC1Fwd and TgMLC1DHFR3’UTRRev. The 3’
untranslated region (UTR) of the dihydrofolate reductase (DHFR)
gene was amplified from TUBIMC1YFP/sagCAT [34] using
primers TgMLC1DHFR3’UTRFwd and DHFR3’UTRHindIII.
Amplicons were resolved by agarose gel electrophoresis, excised
and purified using the QIAquick Gel Extraction Kit (QIAGEN,
Valencia, CA) and ‘‘stitched’’ together using the fusion PCR
TachypleginA-2 Inhibits Motility by Binding TgMLC1
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technique as described in [35]. The fused, final product was
ligated with pGRA1/ble [36] via the restriction sites KpnI and
HindIII to generate the intermediate plasmid pGRA1/
ble(TgMLC1minigene). The 3’ flanking region of TgMLC1 was
amplified using genomic DNA as described above with primers
TgMLC13’flankBamHIFwd and TgMLC13’flankXbaIRev, digest-
ed with BamHI to yield a 725 bp DNA fragment and purified by
gel extraction. The 3’ flanking sequence was then ligated with the
intermediate plasmid pGRA1/ble(TgMLC1minigene) via BamHI
to generate the plasmid pFLAGTgMLC1WTAR. Finally, the
tandem tomato (2t) expression cassette was amplified from
pCTR2T [37] using primers GRA1KpnIFwd and SAG3’UTRB-
glIIKpnIRev and cloned nondirectionally into the plasmid
pFLAGTgMLC1WTAR to generate the knock-in plasmid
pFLAGTgMLC1WTAR2tfwd. The forward orientation of the
2t expression cassette was verified by diagnostic restriction digests.
Primers for amplifying the flanking sequences were designed based
on the T. gondii myosin light chain 1 sequence (TgGT1_257680) in
the Toxoplasma Genomics Resource ToxoDB (http://toxodb.org/
toxo/; accessed 2013 Dec 10 [38,39]).
The FLAG-tagged C58S TgMLC1 construct was generated
with the QuikChange site-directed mutagenesis method using
primers TgMLC1C58S2Fwd and TgMLC1C58S2Rev, according
to the manufacturer’s instructions (Agilent Technologies, Santa
Clara, CA). Constructs were verified by diagnostic restriction
digests and sequencing.
100 mg of each of the allelic replacement plasmids was
linearized with BglII and PciI and used for transfection of 26107
RHDku80Dhxgprt parasites. Parasites were resuspended in Cytomix
Buffer (120 mM KCl, 0.15 mM CaCl2, 10 mM potassium
phosphate, pH 7.6, 25 mM HEPES-KOH, pH 7.6, 2 mM
EDTA, 5 mM MgCl2) supplemented with 2 mM ATP and
5 mM reduced glutathione and electroporated using a ECM 630
electroporation system (BTX, Holliston, MA). Transfected para-
sites were used to infect confluent HFF monolayers and subjected
to two rounds of selection in the presence of 50 mg/mL and 5 mg/
mL phleomycin as previously described [36]. Individual parasite
clones were isolated by limiting dilution and FLAG-positive, 2t-
negative recombinants identified by immunofluorescence micros-
copy (see below for details). The desired allelic replacement and
integration events at the TgMLC1 locus were evaluated by
diagnostic PCRs on tachyzoite genomic DNA prepared as
described above, using primer pairs TgMLC15’flankupstrFwd
and GRA1BglIIRev, and TgMLC1+1587(Exon3Start)Fwd and
TgMLC13’flankdownstr+829Rev (P1 and P2, and P3 and P4,
respectively, in Figure S5).
Immunofluorescence microscopy
Confluent HFF monolayers were fixed 24 h post-infection in
PBS containing 2% (v/v) formaldehyde (30 min, 25uC), then
permeabilized in PBS containing 0.25% (v/v) Triton X-100
(15 min, 25uC). Primary and secondary antibodies were diluted in
PBS containing 0.5% (w/v) BSA, passed through a 0.22 mm
syringe filter and incubated with the samples for 30 min at 25uC.
Monoclonal anti-FLAG (Sigma-Aldrich) was used at a dilution of
1:500 and polyclonal rabbit anti-TgGAP45 (a generous gift from
Dr. Con Beckers [5]) was used at a dilution of 1:1,000. Secondary
antibodies conjugated to either Alexa 488 or 546 (Invitrogen) were
diluted 1:500. Images were adjusted for brightness and contrast
and pseudocoloured using Adobe Photoshop CS3.
Cytotoxicity assays
TachypleginA-2 was assayed for cytotoxic effects with the
CellTiter-Glo ATP Luminescent Cell Viability Assay Kit (Promega,
Madison, WI) using a previously described protocol [16] with minor
modifications. Briefly, parasites were harvested by syringe release of
infected HFF monolayers through a 27-gauge needle, filtered
through a 3 mm Nuclepore filter (Whatman, Piscataway, NJ),
centrifuged at 1,000 x g for 4 min, and washed and resuspended at a
concentration of 16107 parasites/mL in HH+1% (v/v) dialyzed
FBS (Invitrogen). 10 mL of the parasite suspension was mixed with
15 mL of HH containing 25 mM, 50 mM, 100 mM tachypleginA-2
or an equivalent amount of DMSO and incubated for 30 min at
25uC. Two negative controls were used: a ‘‘no parasite’’ control
(10 mL of HH in place of the parasite suspension) and a ‘‘heat-killed
parasite’’ control (10 mL parasite suspension that was first incubated
at 100uC for 10 min). 25 mL of CellTiter-Go reagent (buffer and
substrate mix) was added to the parasite suspension, mixed for
2 min and incubated at 25uC for 10 min, followed by luminescence
measurements with a Synergy 2 plate reader (BioTek Instruments,
Winooski, VT).
Figure 1. The tachyplegin analogue tachypleginA-4 is cova-
lently bound to the compound-induced, faster-migrating form
of rTgMLC1. (A) Structures and monoisotopic molecular weights (MW
(mono)) of the tachyplegin analogues tachypleginA-2 (tA-2) and the
alkyne-containing tachypleginA-4 (tA-4). (B) Infected Sf 9 cells express-
ing recombinant FLAG-tagged wild-type TgMLC1 (rTgMLC1) were
treated for 20 min with 100 mM tA-2, tA-4 or an equivalent amount
of DMSO. Cell lysates were then prepared, labelled with biotin-azide
and resolved and visualized by SDS-PAGE/western blotting. Both tA-2
and tA-4 induce a shift in the electrophoretic mobility of rTgMLC1 (anti-
FLAG western blot, top panel: red arrowhead, modified rTgMLC1; blue
arrowhead, unmodified rTgMLC1). However, only the lower form of tA-
4-treated rTgMLC1 was labelled by streptavidin (streptavidin western
blot, middle panel), indicating that the compound is exclusively bound
directly and covalently to the faster-migrating form of rTgMLC1.
doi:10.1371/journal.pone.0098056.g001
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3D motility assays
Parasites were harvested by syringe release of infected HFF
monolayers through a 27-gauge needle, filtered through a 3 mm
Nuclepore filter, centrifuged at 1,000 x g for 4 min, and washed
and resuspended to a concentration of 1-26108 parasites/mL in
3D Motility Media (1X Minimum Essential Medium lacking
sodium bicarbonate, 1% (v/v) FBS, 10 mM HEPES pH 7.0 and
10 mM GlutaMAX L-alanyl-L-glutamine dipeptide) supplement-
ed with 0.3 mg/mL Hoechst 33342. The parasite suspension was
mixed with 3 volumes of 3D Motility Media containing 25 mM,
50 mM, 100 mM tachypleginA-2 or an equivalent amount of
DMSO and incubated for 20 min at 25uC in the dark, followed by
another 3 volumes of Matrigel (BD Biosciences, San Jose, CA),
prechilled on ice. Motility was then imaged, tracked and processed
as previously described [40]. Parasites with a total trajectory
displacement (simple distance from first to last trackpoint) of
greater than 2 mm were considered moving based on analysis of a
heat-killed parasite preparation, as previously described [40].
Parasites with a total trajectory displacement of 2 mm or less were
considered stationary and excluded from further analysis.
Parameters calculated from motility assays were analysed using
two-way ANOVA with Sidak’s multiple comparisons test, with
GraphPad Prism v. 6.01 (La Jolla, CA). Where statistically
significant, multiplicity adjusted P values for comparisons are
indicated with asterisks.
Results
TgMLC1 is a direct target of the tachyplegin analogue
tachypleginA-4
As a first step to identifying the target(s) of the tachyplegin
family of compounds, we used established methods to prepare an
alkyne-derivatized analogue of tachypleginA, tachypleginA-4
(Figures 1A and S1). As previously reported [17] for tachypleginA
and tachypleginA-2 (Fig. 1A), treatment of parasites with 100 mM
tachypleginA-4 inhibited parasite motility and invasion and
resulted in the appearance of a faster-migrating electrophoretic
form of TgMLC1 (data not shown). To generate sufficient
quantities of the different electrophoretic forms of TgMLC1 for
biochemical/proteomic analysis, we tested whether recombinant
FLAG-tagged TgMLC1 (rTgMLC1) expressed in insect cells was
sensitive to compound treatment. As with native TgMLC1 in
parasites, rTgMLC1 underwent a mobility shift in response to
treatment of intact Sf9 cells with either tachypleginA-2 or
tachypleginA-4 (Figure 1B).
TachypleginA-4 contains two alkyne functional groups, which
were incorporated for target identification purposes. If tachyple-
ginA-4 covalently binds to a protein target, then the alkyne(s)
present in the compound could be conjugated to biotin-azide using
copper-based ‘‘click’’ chemistry, and subsequent use of a
streptavidin probe would enable the detection of biotin and hence
protein(s) containing bound tachypleginA-4. Accordingly, we
Figure 2. TachypleginA-2 treatment generates an adduct of 225.118 Da on S57 and/or C58 of rTgMLC1. Low energy collision-induced
dissociation MS/MS spectrum for the doubly-charged ion corresponding to a modified form of the tryptic V46-R59 peptide. This spectrum was
averaged from three independent scans, and is representative of three independent experiments. S, and C, indicate serine and cysteine residues
with a combined adduct mass of 225.118 Da. Coverage of the b- and y-ions in this modified peptide is indicated in green.
doi:10.1371/journal.pone.0098056.g002
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treated rTgMLC1-expressing insect cells with tachypleginA-4,
click labelled extracts with biotin-azide and then determined
whether biotin was bound to a protein co-migrating with
rTgMLC1 by streptavidin western blotting. The major tachyple-
ginA-4/biotin-labelled band from the insect cells co-migrated
precisely with the faster-migrating form of rTgMLC1 (Figure 1B).
These results indicate that the faster-migrating, compound-
induced form of rTgMLC1 contains covalently bound tachyple-
ginA-4 and strongly suggest that the tachyplegin family of
compounds binds directly and covalently to TgMLC1.
TachypleginA-2 binds to and leaves a 225.118 Da adduct
on S57 and/or C58
We next performed liquid chromatography-tandem mass
spectrometry (LC-MS/MS) to map the precise site(s) of compound
binding on TgMLC1. Our previous results suggested that the
VGEYDGACESPSCR tryptic peptide (V46-R59) contained the
site of compound-induced modification [17]. We developed a two-
fold strategy to identify peptides in the faster-migrating form of
rTgMLC1 whose MS/MS spectra indicated that they could be
related to the V46-R59 peptide. If the modification(s) occurred on
the N-terminal half of the peptide, then modified fragment ions
could be found by manually filtering MS/MS spectra for any
characteristic cluster of m/z peaks that correspond to the y-ions
from the C-terminal half of the unmodified V46-R59 tryptic
peptide. Similarly, the MS/MS spectra could be searched for a
cluster of m/z peaks that correspond to the b-ions from the N-
terminal half of the unmodified V46-R59 tryptic peptide, to detect
any modification(s) that occurred on the C-terminal half of the
peptide. Using this approach, we identified a peptide with m/
z=849.351 in the faster-migrating form, whose MS/MS spectra
bore close resemblance to that of the unmodified V46-R59 tryptic
peptide (Figure 2). The coverage of b- and y-ions was sufficient to
determine that, in contrast to the unmodified peptide where both
Figure 3. The modified V46-R59 peptide is quantitatively enriched in the faster-migrating, compound-induced form of rTgMLC1.
(A) The averaged light and heavy isotopic envelopes from the unmodified and modified (faster-migrating) forms of rTgMLC1, respectively, for the
unmodified (left panel) and modified (right panel) V46-R59 peptide. Ratios for dimethyl labelled samples were generated by comparing the average
relative abundances of the light vs. heavy monoisotopic peaks (filled and open stars, respectively). (B) The dimethyl labelling ratios (light:heavy) for
the four most readily identifiable peptides, in addition to the two forms of the V46-R59 peptide in the unmodified and modified rTgMLC1 forms. The
dimethyl labelling ratios for the unmodified and modified V46-R59 peptide (14.04 and , 0.13, respectively, underlined) were strikingly different from
the ratio calculated using the other four peptides (2.2460.27, average6standard deviation). Note that the ratio for the modified peptide was
calculated using the abundance of a peptide (m/z= 864.742) closest to the expected m/z for the light form, since this unmodified form of rTgMLC1
peptide (calculated m/z= 863.371) could not be detected. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0098056.g003
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C53 and C58 were alkylated as a result of iodoacetamide
treatment [17], C53 was a free sulfhydryl, and importantly, an
additional mass of 225.118 Da was observed on C58 and/or S57
(Figure 2). Although we were unable to resolve the exact site(s) of
the modification due to the lack of a high confidence b12 or y2 ion,
the mass and location of the adduct(s) to S57 and/or C58 were
confirmed on this related peptide using high mass accuracy mass
spectrometry and MS3 analysis (Figures S2 and S3). Given the
expected increased propensity for 1,4-conjugate addition of the
soft sulfur atom on C58, compared with the hard oxygen atom on
S57 (reviewed in [41]), it seemed reasonable to conclude that C58
was involved in the reaction with compound. Studies on the
reaction of tachypleginA-4 with a model thiol were consistent with
this assumption (see Figure S4 and Supporting Information S1 for
details).
To quantify the relative abundance of this related peptide, we
performed stable isotope dimethyl labelling on tryptic peptides
from the unmodified and modified (i.e., faster-migrating) forms of
rTgMLC1 with ‘‘light’’ and ‘‘heavy’’ isotopes, respectively [28,29].
Since light and heavy labelled peptides with identical amino acid
Figure 4. Treatment with the heavy tachyplegin analogue D10-tachypleginA-2 increases the mass of the adduct by 5.03 Da. (A)
Structure and monoisotopic molecular weight (MW (mono)) of the heavy analogue D10-tachypleginA-2 (D10-tA-2). (B) Infected Sf 9 cells expressing
rTgMLC1 were treated for 20 min with 100 mM tA-2, D10-tA-2 or an equivalent amount of DMSO and samples were resolved by SDS-PAGE/western
blotting with an anti-FLAG antibody. The unmodified and modified forms of rTgMLC1 are indicated with blue and red arrowheads, respectively. D10-
tA-2 induces an electrophoretic mobility shift of rTgMLC1 similar to that observed upon treatment with tA-2. (C) Low energy collision-induced
dissociation MS/MS spectrum for the doubly-charged ion corresponding to a modified form of the tryptic peptide V46-R59. This spectrum is averaged
from twenty independent scans, and is representative of three independent experiments. S1 and C1 indicate serine and cysteine residues with a
combined adduct mass of 230.149 Da, which corresponds to an increase in mass of five deuterium atoms. Coverage of the b- and y-ions in this
modified peptide is indicated in green.
doi:10.1371/journal.pone.0098056.g004
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sequences should have closely overlapping chromatographic
profiles yet differ in mass, the relative abundance of each peptide
in the unmodified and modified forms can be readily determined
by calculating its light:heavy ratio, in the same way that relative
abundances are calculated with a stable isotope labelling by amino
acids in culture (SILAC) approach [42]. Six pairs of tryptic
peptides were readily identified from the unmodified and modified
forms of rTgMLC1; four of these had similar light:heavy ratios
with the light peptide approximately 2.24 fold more abundant
than the heavy peptide, suggesting the conversion from the
unmodified to the modified form following compound treatment
was in this instance less than 50% (Figure 3). The unmodified
V46-R59 peptide had a light:heavy ratio of 14.04, reflecting a
greater abundance of this peptide in the unmodified form of
rTgMLC1 compared to the faster-migrating, modified form
(Figure 3A). In contrast, the modified V46-R59 peptide was
undetectable in the unmodified form of rTgMLC1 but readily
found in the modified form, with an light:heavy ratio of , 0.13
(Figure 3A). These data show that the peptide containing the
225.118 Da adduct is quantitatively enriched in the faster-
migrating, compound-induced form of rTgMLC1.
Given that the mass of tachypleginA-2 is 317.178 Da, the
225.118 Da adduct on S57 and/or C58 could either have been
derived from a portion of tachypleginA-2 itself or corresponded to
a native posttranslational modification that is induced upon
tachypleginA-2 treatment (e.g., upon binding of tachypleginA-2 to
some other site(s) on TgMLC1). Searches conducted with the
Unimod (http://www.unimod.org/modifications_list.php; ac-
cessed 2013 Dec 10), ABRF Delta Mass (http://www.abrf.org/
index.cfm/dm.home?AvgMass = all; accessed 2013 Dec 10) and
METLIN (http://metlin.scripps.edu/metabo_search_alt2.php;
accessed 2013 Dec 10) databases did not return a combination
of common posttranslational modifications and/or metabolites
that could reasonably account for a total mass of 225.118 Da on
serine and/or cysteine residues (data not shown). However, to
definitively resolve this question we synthesized a ‘‘heavy’’
tachyplegin analogue, D10-tachypleginA-2 (Figure 4A and S1)
that was able to induce the electrophoretic mobility shift
(Figure 4B). This analogue contained five deuterium atoms on
each of its two phenyl ring substituents for an overall increase in
mass of 10.063 Da compared to tachypleginA-2. D10-tachyple-
ginA-2-treated rTgMLC1 samples were subjected to LC-MS/MS
with an instrumentation method optimized for fragmentation of
m/z peaks that corresponded to several possible outcomes: (i) no
change in the adduct mass (+225.118 Da); (ii) the addition of five
deuterium atoms, if one intact phenyl ring were part of the adduct
(+225.118 Da + 5.031 Da = +230.149 Da); (iii) the addition of ten
deuterium atoms, if both intact phenyl rings were present
(+225.118 Da + 10.063 Da = +235.181 Da); and (iv) the addition
of the full mass of the compound (+327.241 Da). The only modified
peptide found in the faster-migrating form of a tachypleginA-2-
treated sample was again one with a 225.118 Da adduct (data not
shown). This peptide was not detected in the heavy analogue-
treated sample. Instead, a new related, modified peptide was present
with an isotopic envelope that had increased by 5.031 Da.
Annotation of the MS/MS spectra revealed the mass increase (for
a new adduct mass of 230.149 Da) localized to S57 and/or C58: in
comparison to the spectra shown in Figure 2, all of the detected
b-ions remained the same except for the b13-ion (whose m/z
increased by 5.031 Da), and the m/z for all of the detected y-ions
increased by 5.031 Da (Figure 4C). Taken together, these data
demonstrate that the tachyplegin analogues or their metabolites
bind directly to rTgMLC1, and this covalent modification results in
formation of an adduct on S57 and/or C58 (see Discussion).
Mutation of C58 prevents the mobility shift and covalent
modification of TgMLC1
To genetically dissect the roles that S57 and C58 play in
compound binding, we assessed the ability of tachypleginA-2 and
tachypleginA-4 to covalently modify rTgMLC1 containing a
mutation at either of these two sites. Like wild-type, rTgMLC1
containing a S57A mutation was able to undergo a mobility shift
in response to either tachypleginA-2 or tachypleginA-4 treatment,
and a streptavidin signal was detected co-migrating with the faster-
migrating, tachypleginA-4-induced form of rTgMLC1 (Figure 5).
S57 is therefore neither required for nor the site of compound
binding to rTgMLC1. In contrast, the electrophoretic mobility of
rTgMLC1 with a C58S mutation did not shift in response to treat-
ment with either of the tachyplegin analogues, and was refractory
to labelling and binding by tachypleginA-4 as shown by the lack of
a co-migrating streptavidin signal (Figure 5). These results strongly
suggest that the compound binds directly to C58 and demonstrate
that when this site is mutated to serine, the compound can no
longer bind covalently to rTgMLC1 or induce a mobility shift.
Parasites expressing TgMLC1 with the C58S mutation are
less sensitive to tachypleginA-2 treatment in a motility
assay
To determine whether the C58S mutation could render para-
sites resistant to compound treatment, we generated knock-in
parasites whose sole endogenous TgMLC1 allele was replaced with
a FLAG-tagged wild-type (WT) or mutant (C58S) TgMLC1
Figure 5. Recombinant TgMLC1 containing a C58S, but not
S57A, mutation prevents covalent modification by tachyple-
ginA-4. Infected Sf 9 cells expressing wild-type rTgMLC1 (rWT), or
rTgMLC1 containing either a S57A (rS57A) or C58S (rC58S) mutation
were treated for 20 min with 100 mM tA-2, tA-4 or an equivalent
amount of DMSO. Cell lysates were then prepared, labelled with biotin-
azide (see text for details) and resolved and visualized by SDS-PAGE/
western blotting. The unmodified and modified forms are indicated
with blue and red arrowheads, respectively. Treatment of rS57A with tA-
2 or tA-4 resulted in a TgMLC1 electrophoretic mobility shift and
labelling of the faster-migrating of TgMLC1 similar to that observed for
rWT, as shown in the anti-FLAG and streptavidin blots, respectively.
However, not only did rC58S not shift in response to tA-4 treatment,
but no streptavidin signal was detected, indicating that tA-4 was not
covalently bound to rC58S. The lanes shown were from the same blot,
and were exposed and adjusted for brightness and contrast identically.
Results shown are representative of three independent experiments.
doi:10.1371/journal.pone.0098056.g005
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Figure 6. Parasites expressing TgMLC1 with the C58S mutation are significantly less sensitive to the motility-inhibiting effect of
tachypleginA-2. (A) Maximum intensity projections (MIPs) for FLAG-TgMLC1-WT (WT) and FLAG-TgMLC1-C58S (C58S) knock-in parasites in a 3D
motility assay, treated with the indicated concentrations of tA-2. Scale bar = 50 mm. The signal intensities in the MIPs were inverted for better
visualization of parasite trajectories. (B-E) Graphs comparing the (B) percent moving, (C) mean trajectory length, (D) mean velocity and (E) maximum
velocity of WT (white bars) and C58S (grey bars) knock-in parasites in the 3D motility assay. All values from compound-treated samples were
normalized to those for DMSO; see Figure S6 for the non-normalized data. The total number of WT parasites analyzed was 7,123 for DMSO; 4,662 for
25 mM tA-2; 5,255 for 50 mM tA-2 and 4,328 for 100 mM tA-2. The total number of C58S parasites analyzed was 5,484 for DMSO; 3,325 for 25 mM tA-2;
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minigene (Figure S5A). Integration at the desired locus was
confirmed by diagnostic PCR on tachyzoite genomic DNA (Figure
S5B). These parasites were viable, and immunofluorescence
analysis of stable clones showed that both WT and C58S
FLAG-tagged TgMLC1 localize to the parasite periphery (Figure
S5C). As expected, WT TgMLC1 underwent an electrophoretic
mobility shift in response to treatment of the knock-in parasites
with tachypleginA-2, whereas C58S TgMLC1 did not (Figure
S5D).
The WT and C58S knock-in parasites were then treated with
tachypleginA-2 and assayed for their ability to move in a recently
developed 3D Matrigel-based motility assay ([40]; Figure 6A).
When the motility parameters were quantified and normalized to
those of untreated parasites, treatment of WT parasites with
increasing concentrations of tachypleginA-2 was seen to cause a
progressive reduction in the percentage of parasites moving
(Figure 6B; summarized in Table 1), with no detectable effect on
the mean trajectory length, mean velocity or maximum velocity of
the parasites that were moving (Figure 6C-E; Table 1). The C58S
mutation did not affect basal levels of parasite motility in the
absence of compound (see Figure S6 for graphs with non-
normalized motility parameters). However, nearly 1.5 times and
twice as many C58S parasites remained motile in the presence of
50 and 100 mM tachypleginA-2, respectively, relative to WT
parasites. Cytotoxicity assays confirmed that the decrease in
percent moving and differences in sensitivity to compound were
not due to differential toxicity of the compound in the WT and
C58S parasites (data not shown). Although the C58S mutation did
not confer complete insensitivity to tachypleginA-2 treatment,
these data demonstrate that C58 of TgMLC1 is a physiologically
relevant binding site for the small-molecule inhibitor tachyple-
ginA-2.
Discussion
TachypleginA and its analogues were recently identified as
inhibitors of T. gondii invasion and motility [16,17], and we show
here that TgMLC1 is one of the biologically relevant targets of
these compounds using a combination of ‘‘click’’ chemistry, mass
spectrometry and mutational analysis. TachypleginA-2 modifies
TgMLC1 on C58, and a C58S mutation in TgMLC1 reduces
parasite sensitivity to tachypleginA-2 treatment in the 3D motility
assay.
While these experiments identify TgMLC1 as a physiologically
relevant target of the tachyplegin family of compounds, there are
likely to be additional protein targets in T. gondii. Experiments in
which tachypleginA-4/biotin-azide-labelled samples were resolved
by two dimensional electrophoresis revealed streptavidin signals
other than the one co-migrating with TgMLC1 (data not shown),
and tachypleginA has also been shown to inhibit microneme
secretion [16], a process that is not dependent on a functional
myosin motor complex [9]. Given the role that certain micro-
nemal proteins play in motility [43], binding of the compound to
other targets that act either directly in or upstream of signalling
pathways involved in microneme secretion could explain why
C58S knock-in parasites still display some sensitivity to treatment
with the highest concentration (100 mM) of compound.
Dienones such as the tachyplegin analogues are known to have
an affinity for biological thiols, including cysteines [22], and
studies performed with EF24, a curcumin (diferuloylmethane)
analogue structurally similar to tachypleginA-2, suggested that it
could serve as a Michael acceptor and react with thiol-containing
molecules such as glutathione and thioredoxin 1 [44,45]. This
reactivity is expected to decrease significantly when the thiol group
is replaced with a hydroxyl group [46–49], consistent with both
our model thiol studies (Figure S4) and our observation that the
C58S mutation (but not S57A) disrupts the binding of rTgMLC1
by tachypleginA-4.
Unexpectedly, an adduct of 225.118 Da rather than 317.178 Da
(i.e., the intact mass of tachypleginA-2) was observed on C58. One
possible explanation for the generation of an adduct of this size is
shown in Figure S7. This proposal is consistent with the
observation that treatment with D10-tachypleginA-2 resulted in
a 5.031 Da increase in the adduct mass (i.e., corresponding to five
deuterium atoms), as only one of the two aromatic rings is present
4,587 for 50 mM tA-2 and 4,417 for 100 mM tA-2. Data shown are the results of three independent experiments, with each experiment performed in
triplicate. Datasets were compared by two-way ANOVA (** p,0.001); error bars = standard deviation.
doi:10.1371/journal.pone.0098056.g006
Table 1. Summary of 3D motility parameters for TgMLC1 knock-in parasite lines.
WT C58S
concentration tA-2
used 0 mM 25 mM 50 mM 100 mM 0 mM 25 mM 50 mM 100 mM
n total trajectories
analyzed
7,123 4,662 5,255 4,328 5,484 3,325 4,587 4,417
% movinga 58.0612.3%d 48.2610.0% 37.266.7% 17.265.8% 58.266.2%d 59.364.7% 55.463.1% 32.569.4%
% fittable moving
parasitesb
83.361.1% 75.467.3% 76.266.6% 75.965.1% 81.062.5% 84.060.8% 82.061.3% 83.563.6%
mean trajectory
length (mm)c
26.161.7 27.464.5 25.563.0 17.563.6 29.562.9 32.563.2 30.062.1 24.160.6
mean velocity (mm/s)c 0.860.1 0.860.1 0.760.1 0.560.1 0.960.2 0.960.1 0.960.1 0.760.1
max velocity (mm/s)c 2.160.1 2.160.1 1.960.3 1.860.2 2.360.2 2.460.2 2.260.1 1.960.0
aPercentage of parasites whose trajectories have a total displacement of . 2 mm.
bPercentage of parasites with a sufficient number of trackpoints ($ 12) to apply a modified Fourier fit.
cCalculated for fittable trajectories from moving parasites only.
dValues expressed are mean 6 SD.
doi:10.1371/journal.pone.0098056.t001
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in the final adduct. This covalent modification of TgMLC1 by
compound appears to only occur when compound is added to
intact cells and not to cell lysates. This was true both for TgMLC1
in parasites [17] and rTgMLC1 expressed in Sf 9 cells (Fig. 1B and
data not shown). Perhaps some additional factor present in both T.
gondii and Sf 9 cells is needed for binding of the compound, or
some condition required for the reaction shown in Figure S7 is met
in the cytosol but not in cell extracts. Detailed analytical studies
with model peptides, different tachyplegin analogues and a variety
of reaction conditions will ultimately be required to elucidate the
precise structure of the tachyplegin-derived adduct on TgMLC1
and the mechanism by which it forms in intact cells.
TachypleginA was previously shown to decrease the duty ratio
of the T. gondii myosin motor complex by 50% in in vitro motility
assays [17], and we showed here that the compound causes a dose-
dependent decrease in the percentage of parasites moving in a
Matrigel-based motility assay. Nevertheless, the parasites that
moved did so with parameters indistinguishable from those of
untreated parasites. In other words, compound treatment signif-
icantly decreases the percentage of moving parasites without
altering the other motility parameters that can be measured in the
3D assay. This phenotype is largely reversed in the C58S parasites.
How binding of tachypleginA-2 to C58 might affect myosin motor
function is unclear. C58 is found in the N-terminal extension of
TgMLC1, a unique region upstream of the relatively more
conserved EF-hand motifs that are a hallmark of calmodulin-like
proteins. Although the crystal structure of the C-terminal fragment
of P. yoelii MyoA in complex with the C-terminal half of P.
falciparum myosin light chain (PfMTIP) has been solved [50], it
lacks the N-terminal extension, making it difficult to predict from
these data how covalent modification of C58 of TgMLC1 could
affect the interaction of this protein with other components of the
myosin motor complex. One intriguing observation is that this
cysteine is in close proximity to S55 and S57, two known sites of
phosphorylation on TgMLC1 [3,51]. Future investigation of
whether tachyplegin-associated modification of C58 affects the
phosphorylation state of these nearby serine residues may shed
light on the mechanisms underlying the regulation and function of
this class XIV myosin motor complex.
Supporting Information
Figure S1 Synthetic scheme for the tachyplegin ana-
logues used in this study: tachypleginA-2, tachypleginA-4
and D10-tachypleginA-2.
(TIF)
Figure S2 High mass accuracy mass spectrum of the
modified V46-R59 tryptic peptide confirms the site(s) of
modification as S57 and/or C58. Low energy collision-
induced dissociation MS/MS spectrum for the doubly-charged ion
corresponding to a modified form of the tryptic V46-R59 peptide.
Both the precursor (MS) and product (MS/MS) scans were
performed in the Orbitrap with the lock mass internal calibration
feature enabled for high mass accuracy (i.e., , 3 ppm in these
experiments). This spectrum was averaged from three independent
scans, and is representative of three independent experiments. S,
and C, indicate serine and cysteine residues with a combined
adduct mass of 225.118 Da. Coverage of the b- and y-ions in this
modified peptide is indicated in green.
(TIF)
Figure S3 MS3 analysis of the y7 ion from the modified
V46-R59 tryptic peptide confirms the site(s) of modifi-
cation as S57 and/or C58. Low energy collision-induced
dissociation MS3 (i.e., MS/MS/MS) spectrum for the y7 ion
derived from the doubly-charged, modified form of the tryptic
V46-R59 peptide. The precursor (MS) scan was performed in the
Orbitrap and the two product scans (MS2 and MS3) were
performed in the LTQ for maximum sensitivity. This spectrum
was averaged from twelve independent scans, and is representative
of three independent experiments. S, and C, indicate serine and
cysteine residues with a combined adduct mass of 225.118 Da.
Coverage of the b- and y-ions in this modified peptide is indicated
in green. Whereas the presence of unexplained fragments is
apparent, fragment ions consistent with MS3 fragmentation of the
MS2 y7 ion are distinct.
(TIF)
Figure S4 TachypleginA-4 reacts with thiol-containing
compounds. Previous studies with close structural analogues of
the tachyplegin family have shown that this type of compound is
susceptible to reaction with thiols, such as those on cysteine
residues [32,33]. To explore this possibility, tachypleginA-4 was
reacted with a slight excess of the model thiol-containing
compound ethyl-2-mercaptoacetate in the presence of the weak
base triethylamine. (A) Reaction scheme showing the formation of
the diastereomeric mixture of 1,4-conjugated addition derived
products S1 on reaction of tachypleginA-4 with ethyl-2-mercap-
toacetate in the presence of triethylamine (Et3N) in dichlorometh-
ane (DCM). It is important to note that no evidence to support the
formation of the alkynylated thiol S2 was gained in this reaction
consistent with the conclusion that TgMLC1 is not labelled by
alkynyl transfer from tachypleginA-4 to the protein (as shown in
the alternate reaction pathway, data not shown); (B) Chemical
structure of the six possible diastereoisomers of S1. These results
demonstrate that tachypleginA-4 can covalently bind to thiols and
are consistent with C58 as a feasible site of compound binding. To
the best of our knowledge and consistent with the Hard Soft Acid
Base (HSAB) theory as reviewed in [41], no examples of the
intermolecular 1,4-conjugate addition of an alcohol (such as serine)
to compounds like tachypleginA-4 are known.
(TIF)
Figure S5 Generation and characterization of TgMLC1
knock-in parasite lines. (A) Schematic depicting the TgMLC1
locus prior to and after integration of the knock-in DNA fragment
by double homologous recombination. White boxes represent
regions flanking the TgMLC1 gene used to target the phleomycin
resistance cassette to the TgMLC1 locus. Dark grey boxes represent
predicted exons in the TgMLC1 locus. Light grey boxes represent
elements introduced after double homologous recombination.
DHFR = dihydrofolate reductase; UTR = untranslated region;
bleR = phleomycin resistance cassette; SAG1 = surface antigen
1. (B) PCRs using the primer combinations indicated in (A) and
genomic DNA extracted from the clonal parental
RHDku80Dhxgprt (Dku80), FLAG-tagged wild-type TgMLC1
(WT) or FLAG-tagged C58S TgMLC1 knock-in (C58S) parasites.
Expected amplicon sizes for P1 + P2 PCR = no product for
intact, endogenous TgMLC1 locus, and 3.5 kb for the TgMLC1
locus after integration. Expected amplicon sizes for P3 + P4 PCR
= 1.5 kb for intact, endogenous TgMLC1 locus, and 2.9 kb for the
TgMLC1 locus after integration. Numbers on the left indicate size
of DNA fragments in kilobases (kb); L = ladder; (-) = no
template. (C) Dual immunofluorescence labelling of knock-in
parasites expressing FLAG-TgMLC1-WT (WT) or FLAG-
TgMLC1-C58S (C58S) with antibodies against FLAG (green) or
TgGAP45 (magenta). Both the wild-type and mutant TgMLC1
localize to the parasite periphery. Note that colocalization of
signals from the green and magenta channels produces a white
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signal in the overlay. Scale bar = 5 mm. (D) WT or C58S
parasites were treated with 100 mM tA-2 or an equivalent amount
of DMSO, and samples were resolved by SDS-PAGE/western
blotting. The unmodified and modified forms of TgMLC1 are
indicated by blue and red arrowheads, respectively. Flag-tagged
wild-type TgMLC1 was able to undergo an electrophoretic
mobility shift in response to the compound whereas the C58S-
containing TgMLC1 was not. TgACT1 = T. gondii actin loading
control.
(TIF)
Figure S6 Non-normalized motility parameters of the
knock-in parasites upon tachypleginA-2 treatment.
Graphs comparing the (A) percent moving, (B) mean trajectory
length, (C) mean velocity and (D) maximum velocity of WT
(white bars) and C58S (grey bars) knock-in parasites in the 3D
motility assay. The total number of WT parasites analyzed was
7,123 for DMSO, 4,662 for 25 mM tA-2, 5,255 for 50 mM tA-2
and 4,328 for 100 mM tA-2; the total number of C58S parasites
analyzed was 5,484 for DMSO, 3,325 for 25 mM tA-2, 4,587 for
50 mM tA-2 and 4,417 for 100 mM tA-2. Data shown are the
results of three independent experiments, with each experiment
performed in triplicate. Datasets were compared by two-way
ANOVA (* p , 0.05); error bars = standard deviation.
(TIF)
Figure S7 One possible mechanism to explain the
observed formation of tachyplegin-derived adducts on
C58 of TgMLC1. After formation of an initial TgMLC1-
tachypleginA-2 adduct (S3 all Hs) or a TgMLC1-D10-tachyple-
ginA-2 adduct (S3 all Ds), subsequent nucleophile-induced loss of
the second aromatic ring could occur to give S5 via S4. Oxidation
of S5 would then be required to produce the final adducts (the
proposed adduct is shown in red for tachypleginA-2 (all Hs) or blue
for D10-tachyplegin A-2 (all Ds)). This speculative explanation is
consistent with the experimentally observed mass shifts.
(TIF)
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